INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Trading 07-17 13:39:02

87.750

-6.450

-6.85%

High95.200	Low87.300	Vol11.98M
Open94.700	D1 Closing94.200	Amplitude8.39%
Mkt Cap152.77B	Tradable Cap152.77B	Total Shares1.74B
T/O1.08B	T/O Rate0.69%	Tradable Shares1.74B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":87.75,"timestamp":1784266742346,"preClose":94.2,"halted":0,"volume":11978734,"delay":0,"changeRate":-0.06847133757961786,"floatShares":1741000000,"shares":1741000000,"eps":0.543941902781916,"marketStatus":"Trading","change":-6.45,"latestTime":"07-17 13:39:02","open":94.7,"high":95.2,"low":87.3,"amount":1078743193,"amplitude":0.083864,"askPrice":87.75,"askSize":500,"bidPrice":87.7,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":0.543941902781916,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784275800000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":94.2,"openAndCloseTimeList":[[1784251800000,1784260800000],[1784264400000,1784275200000]],"volumeRatio":1.001021,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5908,"impliedVolPercentile":0.7796},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"1144136123","title":"Movement Alert｜Innovent Biologics Falls 3.45% in Regular Trading, Trading at HK$89.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1144136123","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144136123?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:30","pubTimestamp":1784255408,"startTime":"0","endTime":"0","summary":"On July 17, Innovent Biologics fell 3.45% in regular trading, trading at HK$89.85/share, with turnover of HK$499 million.Within the Biotechnology sector where Innovent Biologics belongs, the overall...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652260304","title":"Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2652260304","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652260304?lang=en_us&edition=fundamental","pubTime":"2026-07-16 22:28","pubTimestamp":1784212112,"startTime":"0","endTime":"0","summary":"Innovent Biologics recently announced an exclusive license agreement granting Spero Therapeutics rights to develop and commercialize IBI355 outside Greater China, with Innovent eligible for up to approximately US$1.10 billion in upfront and milestone payments plus tiered royalties.\nThe arrangement effectively turns IBI355 into a globally partnered asset, allowing Innovent to keep Greater China rights while leveraging Spero’s international development plans in IgG4-related disease and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-is-up-91-after-striking-us110-bi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-is-up-91-after-striking-us110-bi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","HK0000165453.HKD","CHAT","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","LU2097828474.EUR","KURE","LU0502904849.HKD","LU2097828714.EUR","BK1583","BK1589","AGIX","BK1161","ARTY","VTHR","LU2488822045.USD","AIPO","LU2328871848.SGD","01801","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135186577","title":"CLSA Raises Innovent Biologics Price Target to HK$139.9, Citing New Overseas Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1135186577","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135186577?lang=en_us&edition=fundamental","pubTime":"2026-07-16 14:30","pubTimestamp":1784183417,"startTime":"0","endTime":"0","summary":"CLSA has issued a research report noting that Innovent Biologics (01801) announced on July 14th that it has licensed the rights to its immunology drug IBI355 outside Greater China to Spero...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU0502904849.HKD","EWH","LU2097828474.EUR","BK1589","BK1161","LU2097828631.EUR","LU1969619763.USD","LU2242644610.SGD","LU2488822045.USD","HK0000165453.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828714.EUR","BK1583","KURE","LU2097828557.USD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193634490","title":"Movement Alert｜Innovent Biologics Falls 3.09% in Regular Trading, Trading at 94.4 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1193634490","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193634490?lang=en_us&edition=fundamental","pubTime":"2026-07-16 10:16","pubTimestamp":1784168211,"startTime":"0","endTime":"0","summary":"On July 16, Innovent Biologics fell 3.09% in regular trading, trading at 94.4 HKD/share, with Turnover of 7.82 billion HKD.Within the Biotechnology sector where Innovent Biologics belongs, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184389225","title":"Hong Kong Market Analysis: Longxun's IPO Valuation Sets Benchmark, Stirring Tech Sector; \"Lab Monkey\" Prices Drive CXO Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389225","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184389225?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:43","pubTimestamp":1784119436,"startTime":"0","endTime":"0","summary":"The Hong Kong market has recently shown signs of moving independently, with its current trend aligning well with its internal structure. While the A-share market declined, Hong Kong stocks have...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0390135332.USD","HK0000306701.USD","06066","LU1235295612.USD","BK4588","01801","SG9999011746.SGD","HK0000252160.HKD","BK1535","LU2488822045.USD","BK1589","LU0359201612.USD","SG9999003461.SGD","LU2242644610.SGD","LU0502904849.HKD","LU1023057109.AUD","SG9999001093.SGD","BK1147","LU0390135688.USD","IPOS","LU2097828714.EUR","HK0000306685.HKD","BK1583","LU0300738514.USD","BK1103","LU0359202008.SGD","HK0000252152.HKD","LU2097828631.EUR","LU1046422090.SGD","BK1501","LU1969619763.USD","BK1161","LU0455707207.USD","SG9999002950.SGD","LU0359201885.HKD","CXO","BK1564","LU0390135506.SGD","SG9999002828.SGD","LU2097828474.EUR","LU2328871848.SGD","06127","LU0300738605.USD","BK1516","02343","VXUS","03908","BK1576","LU2097828805.USD","LU2097828557.USD","HK0000320223.HKD","BK1141","HK0000500386.USD","HK0000320264.USD","KURE","HK0000165453.HKD","LU0049112450.USD","KCAI","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158775929","title":"Hong Kong Market Rises 1.4% on Fed Policy Shift Hopes; Healthcare and Consumer Stocks Lead Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1158775929","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158775929?lang=en_us&edition=fundamental","pubTime":"2026-07-15 16:55","pubTimestamp":1784105753,"startTime":"0","endTime":"0","summary":"Hong Kong's three major indices climbed steadily throughout the session, closing higher on Monday. The gains followed a cooler-than-expected US inflation report, which significantly reduced...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HHImain","LU2097828631.EUR","BK1135","LU0502904849.HKD","BK0216","MCHmain","LU2242644610.SGD","02648","BK1515","BK4588","BK1142","BK1589","02833","09115","09939","603127","BK1576","KURE","06127","159938","03323","07500","83115","BK1161","BK1591","BK4585","BK1563","HSI","MHImain","LU2097828557.USD","03419","02800","BK1128","03037","BK1503","01801","BK1237","LU2097828714.EUR","SG9999001069.SGD","KCAI","06066","BK1141","BK1583","LU0455707207.USD","LU2328871848.SGD","VXUS","01896","BK1574","BK1516","BK1564","LU2097828805.USD","BK1147","BK1581","513600","03115","07200","LU1969619763.USD","SG9999001093.SGD","HSImain","82800","07300","LU2097828474.EUR","LU2488822045.USD","BK1594","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651375604","title":"Innovent Biologics Shares Surge on Spero Deal That Could be Worth $1.1 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2651375604","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651375604?lang=en_us&edition=fundamental","pubTime":"2026-07-15 14:48","pubTimestamp":1784098080,"startTime":"0","endTime":"0","summary":"Shares of Innovent Biologics jumped Wednesday after the Chinese biopharma firm reached a licensing agreement with U.S.-listed Spero Therapeutics that could be worth $1.1 billion.Innovent's stock climb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","LU2097828805.USD","01801","HK0000165453.HKD","LU2242644610.SGD","BK4139","LU2097828714.EUR","BK1589","SPRO","LU2097828557.USD","BK1583","LU2097828474.EUR","LU1969619763.USD","LU2488822045.USD","BK1161","LU2097828631.EUR","LU0455707207.USD","LU2328871848.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101227446","title":"Innovative Drug Stocks Surge Following Inclusion in National Essential Medicines List, Accelerating Grassroots Access","url":"https://stock-news.laohu8.com/highlight/detail?id=1101227446","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101227446?lang=en_us&edition=fundamental","pubTime":"2026-07-15 10:56","pubTimestamp":1784084190,"startTime":"0","endTime":"0","summary":"Shares of innovative drug companies are leading gains in the Hong Kong market.SKB BIO (06990) rose 10.5% to HK$550.5, while INNOVENT BIO (01801) gained 8.38% to HK$97.6. AKESO (09926) advanced 7.88%...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2242644610.SGD","LU2097828631.EUR","KURE","LU1720050803.USD","LU1961090484.USD","LU2488822045.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0561508036.HKD","BK4585","LU2097828714.EUR","LU2097828557.USD","LU2476274308.USD","06990","LU2097828805.USD","LU0417516902.SGD","LU2399975544.HKD","LU2476274720.SGD","LU0417516571.SGD","LU0348825331.USD","MEDX","01801","HK0000165453.HKD","VXUS","LU0417516738.SGD","LU1969619763.USD","BK1574","LU2097828474.EUR","IBBQ","LU0348827113.USD","BK1161","BK1589","LU0348735423.USD","LU2328871848.SGD","LU2778985437.USD","BK1593","LU0455707207.USD","LU0540923850.HKD","LU0348784397.USD","LU0348767384.USD","LU1794554557.SGD","IE00B543WZ88.USD","159992","IE00BPRC5H50.USD","KCAI","LU0196878994.USD","09926","01530","BK4588","06978","LU0502904849.HKD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133399981","title":"Innovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1133399981","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133399981?lang=en_us&edition=fundamental","pubTime":"2026-07-15 09:40","pubTimestamp":1784079655,"startTime":"0","endTime":"0","summary":"Shares of Innovent Biologics (ASX: 01801) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million. Recent Developments On July...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","KURE","LU2097828805.USD","VXUS","01801","LU0455707207.USD","BK1161","BK4588","LU2097828714.EUR","LU2488822045.USD","LU2097828631.EUR","LU2097828474.EUR","BK4585","LU2328871848.SGD","LU2097828557.USD","BK1589","HK0000165453.HKD","LU0502904849.HKD","BK1583","LU2242644610.SGD","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165017200","title":"Movement Alert｜Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1165017200","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165017200?lang=en_us&edition=fundamental","pubTime":"2026-07-15 09:38","pubTimestamp":1784079529,"startTime":"0","endTime":"0","summary":"On July 15, Innovent Biologics rose 3.78% in regular trading, trading at HKD 93.75/share, with turnover of HKD 340 million.The movement was driven by the announcement on July 14 that Innovent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651172766","title":"Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651172766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651172766?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:43","pubTimestamp":1784025786,"startTime":"0","endTime":"0","summary":"Spero licenses Innovent's experimental immune disease drug for up to $1.1 billionJuly 14 (Reuters)-Spero TherapeuticsSPRO.Ohas licensed rights outside Greater China to develop and commercialize Innove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nL4N43G0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2488822045.USD","LU0455707207.USD","BK1589","BK1583","LU2097828714.EUR","01801","SPRO","LU2097828557.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828805.USD","KURE","LU2097828631.EUR","BK4139","LU1969619763.USD","LU2242644610.SGD","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651714291","title":"Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651714291","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651714291?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:01","pubTimestamp":1784023267,"startTime":"0","endTime":"0","summary":"Innovent Biologics licenses anti-CD40L antibody IBI355 to Spero in deal worth about USD 1.1 billionInnovent Biologics signed an exclusive license with Spero Therapeutics for IBI355 (SP001), a Phase 2-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL8vw8t6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0502904849.HKD","LU2097828557.USD","01801","LU2097828714.EUR","LU2097828631.EUR","LU1969619763.USD","LU2328871848.SGD","BK4139","LU2097828805.USD","BK1147","LU0455707207.USD","KURE","LU2097828474.EUR","01911","BK1161","SPRO","LU2242644610.SGD","HK0000165453.HKD","BK1589","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651904171","title":"Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2651904171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651904171?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023228,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G0H9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2328871848.SGD","LU2097828557.USD","LU2097828805.USD","LU0502904849.HKD","LU1969619763.USD","LU2242644610.SGD","SPRO","LU0455707207.USD","BK4139","LU2097828631.EUR","BK1583","LU2488822045.USD","BK1589","LU2097828474.EUR","LU2097828714.EUR","BK1161","01801","KURE","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171488","title":"Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651171488?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023228,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G0H9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828805.USD","BK4139","SPRO","KURE","BK1161","LU0502904849.HKD","LU1969619763.USD","LU2097828474.EUR","BK1589","LU2328871848.SGD","LU2488822045.USD","LU2097828557.USD","HK0000165453.HKD","LU2097828631.EUR","LU2242644610.SGD","LU2097828714.EUR","BK1583","LU0455707207.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171136","title":"Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651171136?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023228,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G0H9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRO","BK1161","LU2097828631.EUR","LU2097828474.EUR","01801","LU2488822045.USD","LU0502904849.HKD","BK4139","BK1589","LU2097828557.USD","LU2097828805.USD","KURE","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","LU2097828714.EUR","LU0455707207.USD","LU2242644610.SGD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171906","title":"Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651171906?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G01Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828631.EUR","BK1161","LU2488822045.USD","SPRO","LU2097828805.USD","BK1583","LU0455707207.USD","LU0502904849.HKD","BK4139","LU2097828474.EUR","LU2328871848.SGD","BK1589","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","LU2097828714.EUR","01801","KURE","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651133171","title":"Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2651133171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651133171?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G01Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRO","BK1161","LU2097828631.EUR","LU2097828474.EUR","01801","LU2488822045.USD","LU0502904849.HKD","BK4139","BK1589","LU2097828557.USD","LU2097828805.USD","KURE","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","LU2097828714.EUR","LU0455707207.USD","LU2242644610.SGD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651172875","title":"Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2651172875","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651172875?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023200,"startTime":"0","endTime":"0","summary":"Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326657/0/en/Spero-Therapeutics-and-Innovent-Biologics-Announce-Exclusive-License-for-SP001-IBI355-a-Phase-2-Ready-Third-Generation-Anti-CD40L-Antibody.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828805.USD","LU2097828714.EUR","KURE","LENZ","LU2242644610.SGD","BK1161","BK4539","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","01801","BK1583","LU2097828557.USD","LU1969619763.USD","BK1589","BK4139","LU0502904849.HKD","BK4007","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650150371","title":"Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650150371","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650150371?lang=en_us&edition=fundamental","pubTime":"2026-07-12 09:35","pubTimestamp":1783820100,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) has drawn fresh attention after securing exclusive commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China. This adds a reimbursed oncology product to its existing portfolio.\nSee our latest analysis for Innovent Biologics.\nThe Verzenios agreement lands at a time when Innovent Biologics’ share price has a 30 day share price return of 22.96% and a year to date share price return of 13.83%. Its 3 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-undervalued-after-securing-ch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-undervalued-after-securing-ch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2097828714.EUR","LU2242644610.SGD","DCF","KURE","LU2488822045.USD","LU0502904849.HKD","BK1161","01801","LU2097828631.EUR","BK1583","BK1589","HK0000165453.HKD","LU2328871848.SGD","LU0455707207.USD","LU2097828805.USD","LU1969619763.USD","LU2097828557.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902547","title":"Nomura Adjusts Innovent Biologics' Price Target to HK$123.17 From HK$114.64, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902547","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650902547?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:14","pubTimestamp":1783664052,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) has an average rating of buy and mean price target of HK$119.69, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","LU2097828631.EUR","LU2097828557.USD","BK1161","HK0000165453.HKD","LU0502904849.HKD","LU2488822045.USD","LU1969619763.USD","LU2097828714.EUR","01801","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","BK1583","KURE","LU2328871848.SGD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0909},{"period":"1month","weight":0.233},{"period":"3month","weight":0.0295},{"period":"6month","weight":0.0525},{"period":"1year","weight":0.0928},{"period":"ytd","weight":0.2354}],"compareEarnings":[{"period":"1week","weight":0.0407},{"period":"1month","weight":0.021},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0684},{"period":"1year","weight":0.02},{"period":"ytd","weight":-0.0243}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.031726},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}